Novavax Inc.

Novavax closes offering for 6.8 million shares

Miami Herald (Free subscription) | 11 hours ago

Biotech drug developer Novavax Inc. said Wednesday it closed a public offering for 6.8 million shares of common stock.

• Novavax raises $21 million in stock offering - Market Watch
• NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock - PR News Wire
• See the 5 articles on the same subject

Novavax closes offering for 6.8 million shares

Seattle Times (Free subscription) | 11 hours ago

Biotech drug developer Novavax Inc. said Wednesday it closed a public offering for 6.8 million shares of common stock.

Novavax closes offering for 6.8 million shares

Seattle Post-Intelligencer (Free subscription) | 11 hours ago

ROCKVILLE, Md. -- Biotech drug developer Novavax Inc. said Wednesday it closed a public offering for 6.8 million shares of common stock.

Novavax closes offering for 6.8 million shares

San Fransisco Chronicle (Free subscription) | 11 hours ago

Biotech drug developer Novavax Inc. said Wednesday it closed a public offering for 6.8 million shares of common stock. The company announced the offering, at $3.30 per share, Nov. 20. At the time, it was a 12 percent discount to the stock's prior closing... Stock - Initial public offering - Common stock - Business - Investing

Novavax raises $21 million in stock offering

Market Watch (Free subscription) | 13 hours ago

BOSTON (MarketWatch) -- Novavax Inc. said early Wednesday that it has closed on its previously-announced public offering of 6.8 million common shares priced at $3.30 a share. The vaccine developer said it received roughly $21 million from the transaction, which it will use in part to fund its VLP-vaccine research program. Market Pulse Stories are Rapid-fire, short news bursts on stocks...

NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock

PR News Wire (Free subscription) | 13 hours ago

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that on November 25, 2009, it closed its previously announced public offering of 6,800,000 shares of its common stock at $3.30 per share. Novavax received net proceeds from the sale of the shares, after underwriting discounts, commissions and estimated offering expenses, of approximately...

NOVAVAX Reports Positive Clinical Results From Pivotal Study Of H1N1 Influenza Vaccine In Mexico

Medical News Today (Free subscription) | 12/03/2009

Novavax, Inc. (Nasdaq: NVAX) reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and...

• NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico - PR News Wire

Novavax reports positive H1N1 vaccine study results

The Washington Business Journal (Free subscription) | 12/02/2009

Novavax Inc. announced Wednesday that its H1N1 flu vaccine proved safe and effective in a study conducted in Mexico. The news sent shares of the Rockville biotech higher. (NVAX)

• NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico - PR News Wire

Novavax Porks Swine Flu (NVAX)

Volume Spike Investor (Free subscription) | 12/02/2009

Novavax, Inc. (NASDAQ: NVAX) is trading up again on swine flu or H1N1 news. The company issued a press release showing positive clinical results from a pivotal study of H1N1 influenza vaccine in Mexico. At 8:21 AM EST we have seen 319,000 shares trade hands and the stock is up 7.1% at $3.44. Average volume [...]

NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico

PR News Wire (Free subscription) | 12/02/2009

ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico...

Biggest Biotech Stocks Gainers today were CTIC, SPPI, NVAX : by Penny Stock Pick Alert

Radon Mitigation Pittsburgh (Free subscription) | 12/02/2009

( EMAILWIRE.COM , December 02, 2009 ) Dallas, TX - Cell Therapeutics, Inc. (NASDAQ:CTIC) climbed 5.73% to $1.09. The stock hit an intraday high and an intraday low of $1.09 and $1.05 respectively. In the last six months the stock went down over 48%. Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company's research, development,...

Pre Market Stock Gainers & Losers - 12/2/09

Stock Market Analysis (Free subscription) | 12/02/2009

Below is a list of some of the largest stock gainers and losers so far in pre market for December 2, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 12/2/09 Dyax Corp. (DYAX) - Dyax gets FDA marketing nod on genetic disease drug Santarus Inc. (SNTS) - Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC G-III Apparel...

The first pandemic since 1968 - a timeline for 2009

EconoSpeak (Free subscription) | 12/02/2009

... some European countries, while other countries report sharp increases. 2009 – November 17th. Novavax, Inc., announced it will begin studies in Mexico on a new vaccine against H1N1. Initially, about 1,000 people will participate. 2009 – November 12th. Headlines state CDC officials calculate over 4,000 deaths (as opposed to about 1,200 currently reported) are due to H1N1...

Top Day Trader Alerts (DDRX, GMCR, PEET, SOMX, NVAX, DYAX, RFMD, HEB)

24/7 Wall St. (Free subscription) | 12/02/2009

These are this Wednesday’s top day trader and active trader alert stocks with links to VSInvestor.com for more detailed data and analysis: Diedrich Coffee Inc. (NASDAQ: DDRX) is up again as the buyout wars continue from Green Mountain Coffee Roasters (NASDAQ: GMCR) and Peet’s Coffee & Tea (NASDAQ: PEET). Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) is active again, [...]...

• Green Mountain Raises Diedrich Offer - The Wall Street Journal
• Diedrich gets $35-share proposal by Green Mountain - Market Watch
• See the 5 articles on the same subject